Skip to main content
867 search results for:

Calcimimetic 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 27-03-2024 | Calcimimetic | Online First

    Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials

    Patients undergoing dialysis have a higher risk of fractures than the general population [ 1 – 3 ]. Fractures in patients undergoing dialysis are associated with hospitalization and mortality [ 4 ]. Secondary hyperparathyroidism (SHPT), a hallmark …

  2. Open Access 01-06-2022 | Calcimimetic | OriginalPaper

    First-in-Human Phase I Study of the Novel Injectable Calcimimetic Agent Upacicalcet in Healthy Adult Japanese Participants

    Secondary hyperparathyroidism (SHPT) is a major pathological condition in patients with chronic kidney disease (CKD)–mineral and bone disorder [ 1 – 3 ]. As CKD progresses, phosphorus excretion by the kidney is suppressed and calcium absorption …

  3. 01-02-2021 | Calcimimetic | EditorialNotes

    Dialysate calcium concentration during calcimimetic treatment: a neglected issue

  4. 07-01-2021 | Kidney Transplantation | Erratum

    Correction to: Outcomes of parathyroidectomy versus calcimimetics for secondary hyperparathyroidism and kidney transplantation: a propensity-matched analysis

    An Erratum to this paper has been published: https://doi.org/10.1007/s00423-020-02046-z …

  5. 01-09-2020 | Kidney Transplantation | OriginalPaper

    Outcomes of parathyroidectomy versus calcimimetics for secondary hyperparathyroidism and kidney transplantation: a propensity-matched analysis

    Secondary hyperparathyroidism (SHPT) is common in patients with end-stage renal disease (ESRD). SHPT increases the risk of complications such as renal osteodystrophy and vascular calcification in these patients and also decreases quality of life [ …

  6. Open Access 01-01-2021 | Hyperparathyroidism | OriginalPaper

    Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan

    Secondary hyperparathyroidism (SHPT) is a potential complication of hemodialysis or hemodiafiltration in patients with chronic kidney disease. It is characterized by the excessive release of parathyroid hormone (PTH) from the parathyroid glands in …

  7. 01-01-2019 | Pharmacodynamics | Letter

    Comment on: Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study

    The mean percentage reduction (approximately 65%) of intact PTH from baseline for either evocalcet 6 or 12 mg appeared to be similar on day 1 (the first dose of evocalcet) and day 8 (last dose of evocalcet). Apart from minor numerical differences …

  8. Open Access 01-01-2019 | Pharmacodynamics | Letter

    Response to Comments on “Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study”

  9. Open Access 01-10-2018 | OriginalPaper

    Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study

    Chronic kidney disease–mineral and bone disorder (CKD–MBD), an important cause of morbidity and mortality in CKD, includes biochemical abnormalities of calcium, phosphorus, vitamin D, and parathyroid hormone (PTH), associated bone changes, and …

  10. 01-03-2019 | OriginalPaper

    Use of calcimimetics in children with normal kidney function

    The calcium-sensing receptor (CaSR) plays an important role in the homeostasis of serum ionized calcium by regulating parathyroid hormone (PTH) secretion and tubular calcium handling. Calcimimetics, which act by allosteric modulation of the CaSR …

  11. 01-07-2018 | ReviewPaper

    Calcimimetics versus parathyroidectomy: What is preferable?

    Secondary hyperparathyroidism (SHPT) is common among patients with end-stage renal disease (ESRD). SHPT is associated with high-turnover bone disease, interstitial and vascular calcifications, cardiovascular morbidity and mortality. The …

  12. Open Access 01-12-2018 | OriginalPaper

    A case of hyperparathyroidism-associated parkinsonism successfully treated with cinacalcet hydrochloride, a calcimimetic

    Parkinson’s disease is a degenerative disorder that affects the neuromotor system and is characterized by extrapyramidal symptoms including bradykinesia, rigidity, tremor, postural instability, and the freezing phenomenon. The loss of …

  13. 01-07-2018 | OriginalPaper

    A case of hyperinsulinemic hypoglycemia related with a calcimimetic agent

    We herein report a case of a 60-year-old female receiving hemodialysis who developed severe hyperinsulinemic hypoglycemia and lost her consciousness. A calcimimetic agent had been administered for the secondary hyperparathyroidism. The …

  14. 01-04-2018 | OriginalPaper

    Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism

    Secondary hyperparathyroidism (SHPT) is a serious complication in patients undergoing hemodialysis for chronic kidney disease (CKD), and develops as a maladaptive process in response to declining kidney functions [ 1 , 2 ]. SHPT is characterized by …

  15. Open Access 01-12-2017 | OriginalPaper

    Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency

    Chronic kidney disease (CKD) and its progression to end stage renal disease (ESRD) remain a global clinical challenge [ 1 , 2 ]. Regardless of the original kidney insult, one of the major causes leading to the decline of renal function is …

  16. Open Access 01-12-2017 | OriginalPaper

    Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism

    Etelcalcetide, a novel peptide agonist of the calcium-sensing receptor, prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism. Vascular calcification occurs frequently in patients with chronic …

  17. Open Access 01-01-2017 | OriginalPaper

    Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism

  18. 01-04-2016 | ReviewPaper

    Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures

    The actions of extracellular Ca2+ in regulating parathyroid gland and kidney functions are mediated by the extracellular calcium receptor (CaR), a G protein-coupled receptor. The CaR is one of the essential molecules maintaining systemic Ca2+ …

  19. 01-01-2005 | EditorialNotes

    Calcimimetics—fooling the calcium receptor

    The cloning and characterization of a calcium-sensing receptor from bovine parathyroid cells has opened up the possibility of modulating the activity of this receptor protein by organic small molecules, either increasing the sensitivity for …

  20. 01-07-2009 | OriginalPaper

    Calcimimetics: A Review of the Recent Literature

    Mineral and bone disorders, including secondary hyperparathyroidism, are common in chronic kidney disease and contribute to increased mortality. Traditional therapy to control these disorders involves using phosphate binders and vitamin D sterols …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.